Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma

• Status: Completed
• Trial end date: 2021-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study of liposomal bupivacaine for pain control in patients with blunt chest wall trauma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cincinnati
• Collaborator: United States Air Force
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• Anticipated length of stay of at least 72 hours

• Blunt chest wall trauma with two or more rib or sternal fractures

• Demonstrated ability to achieve > 50% predicted inspiratory capacity based on ideal body weight using IS within the first 24 hours of admission

Exclusion Criteria:

• Known allergy to bupivacaine

• Respiratory failure requiring intubation within 24 hours prior to enrollment

• Known or suspected atrioventricular nodal blockade process requiring cardiology evaluation or pacemaker placement

• Hemodynamic instability (defined as new intravenous vasopressor or inotrope requirement or mean arterial pressure < 55 mmHg)

• Signs of active myocardial ischemia or non-ST elevation MI

• > 20 rib fractures

• Weight < 50 kg or > 150 kg

• Pregnancy

• Incarceration